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Isolation of an HLA-A2.1 extracted human
minor histocompatibility peptide*
Purified HLA-A2.1 molecules obtained b> atfinity chromatograpln ot 6 χ Kl1"
Epstein Barr virus (EBV)-transformed Β lymphocytes were used in an attcmpt in
isolate the human HLA-A2.1-restncted minor histocompatibilin (H) peptides
H-Y and HA-2. Fraction 18 of the high-performancc liquid chromatograpln
(HPLC)-separated HLA-A2.1 peptide pool was found to contam the natuial
HA-2 peptide. An HA-2-specific, HLA-A2.1-restnctcd cytotoxicT lymphocue
done lysed HLA-A2.1+ HA-2~ EBV-transformed Β lymphocyte ccll line»
reproducibly and in a concentration-dependent fashion in the presence of traction
18, but not in the presence ot other HPLC fractions. By contrast. H-Ysensitizmg
activity was not found in any fraction. Amino aeid sequencing ot peptide traction
18 revealed a mixture of peptides with maximal length of nine amino acids. in
which the presence of Leu at positions 2 and 9 was dominant. SurprisingK. the
HA-2 peptide could not be mimicked by any of the peptide mixtures synthesized
aecording to the amino aeid sequences found in fraction 18. Our failure to obtain
the actual amino aeid sequence of the human minor Η peptide HA-2 from a
peptide pool with the established pattern for binding to HLA-A2.1 may mdicatc
that this CTL defined minor Η peptide does not represent an abundant
HLA-A2.1 binding peptide.
1 Introduction
Minor histocompatibility (H) antigens represent serious
barriers for succesf ul organ and bone marrow transplanta-
tion (BMT) between individuals matched for the major
histocompatibility complex (MHC) antigens. Minor Η
antigens in general fail to induce Β cell responses and are
characterized by MHC-restricted Τ cell responses [1,2].
Due to the lack of available antibodies, thus far little is
known concerning the genes encoding human minor Η
antigens and their polymorphic gene produets [3]. Recent-
ly, it has become evident that, like virus-speeifie cytotoxic
Τ lymphocytes (CTL) [4, 5], MHC class I-restricted CTL
speeifie for minor Η antigens recognize short protein
Stretches presented by the restricting MHC class I molecule
[6-8j. Another line of investigation revealed that MHC
class I molecules bind and pfesent an allele-specific set of
seif peptides, presumably derived from cellular proteins
[9-11]. We set out to isolate CTL-defined human minor Η
peptides from the pool of peptides naturally presented by
HLA-A2.1. In this report we attempted to characterize two
[I 10773]
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HLA-A2.1-restricted human minor Η peptides, the male-
speeifie antigen H-Y [12] and a hematopoietic tissue-
speeifie antigen termed HA-2 [2, 13].
2 Materials and methods
2.1 CTL and Β cell eultures
EBV-transformed Β cell lines (EBV-BLCL) were expanded
in RPMI1640 supplemented with 10% FCS and antibiotics
in 1 1 roller-bottle flasks. CTL clone 1R35 speeifie for the
male minor Η antigen H-Y in the context of HLA-A2.1 was
obtained from PBMC of a female immunized against H-Yas
a result of multiple transfusions and unsuccesful grafting of
HLA-identical male bone marrow [12]. CTL clone 5H17
speeifie for the HLA-A2.1-restricted minor HA-2 was
obtained from PBMC of a patient shortly after HLA-
identical bone marrow transplantation [2]. Both minor
H-specific CTL lines were established by repeated in vitro
restimulation with the original stimulator PBMC. After
limiting dilution, clones were maintained by weekly Stimu-
lation with allogeneic feeder cells in RPMI 1640 supple-
mented with 15% pooled human serum and 20 U/ml rIL-2.
Immunogenetic data and tissue expression of the HA-2
minor Η antigen were previously described [3, 13].
2.2 Purification of HLA-A2.1 and Isolation of
HLA-A2.1 bound peptides
Pellets of 6 x 1010 EBV-BLCL were ineubated for 45 min at
4 °C at 2 x 108 cells/ml in a Iysis buffer containing 50 mM
Tris, 150 mM NaCl, 0.5% Nonidet P-40,5 mM EDTA, pH 8
and 0.1 mM PMSF and 1 μg/ml of the protease inhibitors
antipain, leupeptin, chymostatin and pepstatin. Centrifu-
gation for 5 min at 500 χ g followed by 60 min at lOOOOxg
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yielded a supernatant which was used to punfy HLA-A2 1
by affinity chromatography The antibodies 7 5 10 1 (anti-
HLA class II) and BB7 2 (anti-HLA-A2 1. [14]) were
coupled at 5 mg/ml to CNBr-activated Sepharose 4B beads
(Pharmacia LKB) The supernatant was sequentially
passed, at a flow rate of 8 ml/h, through columns filled with
Tns-HCl equihbrated beads (10 ml), anti-HLA class II
beads (2 ml) and two columns with anti-HLA-A2 1 beads
(7 and 4 ml) Beads were removed from anti-HLA-A2 1
columns and mcubated for 15 min at 4 °C in 15 ml 0 1%
tnfluoroacetic acid (TFA) Supernatants were separated by
centnfugation over Centncon 10 (Amicon) filters into a
> 10 kDa and a < 10 kDa fraction.The amount ot puntied
HLA-A2 was determined with the BCA protein assay
(Pierce) in the > 10 kDa fraction Punfication grade was
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Figuw I Aftinilv-punficd HLA-A2 1 molecules (a) and HPLC
profilcsof HLA-A2 1 and ot peptideseluted from these molecules
(b) (a) SDS-poivacrylamide gel ( l^X) run under reducing condi-
tions Lanc I Standard markers with indicated molecular weight
(B'oRad) lane 2 unscparatcd Ivsatc lane λ. afhnitv-punfied
HLA-A2 1 > 10 kDa (4 5 ng) lane 4 < 10 kDa matenal eluted
trom 4 s (ig HL Λ-Α2 I. lane S HPLC fraction 24 of HLA-A2 1,
Iane6 HPLC Iraction 19 ot HLA-A2 (b) Reversc-phase HPLC
Separation ol lngh(> 10 kDa)andlow (< 10 kDa) molecular mass
fraUions ot alfinitv-purihed HI Α A2 the void \olume peak
representing salt mjeUion and the tinal peak representing NP40
were tound in all HPl C runs Note that the peak at 19 and 24 ml in
the > 10 kDa III Α-Λ2 1 profile represent [i2m and Η chain
contammateil witti some |')2m respeUi\elv (a laues ^ 6andb top
prolik)
monitored b\ siKer-stamed SDS-PAGE The IO\A and high
molecular weight tractions ot HLA-A2 1 were dned b\
saeuum centntugation and separated b\ rc\crsc-phasc
HPLC using a^LiChrospher 60 RP-Select B. 5 um.
250 χ 4 mm column (E Merck. Darmstadt. FRG) Elu-
tion butters were A. H
:
O , B. ucetonitnle: and C. 2% TFA
in HiO Gradients routinclv used for separations 0-30 mm
linear increase trom 5% to 75% Β or 0-45 min linear
increase trom 20% to 50% B. with 5% butter C being used
throughout all gradients. flow rate 1 0 ml/mm Elution was
monitored b\ a continuous flow spectrophotometer at
214 nm Fractions ot 1 or 0 5 ml were collected and dned b\
\acuum centntugation
2.3 Pepiide sequencing and synthesis
Low molecular weight matenal eluted trom HL A-A2 1 and
separated by HPLC was sequenced by automated Edman
degradation using a pulsed-hquid protein sequencer 477A
equipped with an on-line PTH-amino acid analyzer 120A
(Applied Biosystems) Mixturesot synthetic peptides were
generated dunng mixed syntheses using an AMS 422
Synthesizer (Abimed Analysen-Technik, FRG) and were
puntied by reverse-phase HPLC Four mixtures cach
contained 64 nonapeptides X O L X I X - I X ^ E T L . X(ILX|X^-
X,X4LTL. X„LX|X:X.X4ATL and X(,LX,X:X^X4lTL. re-
spectively, wherem position X
o
 is A. X| can carry cither F
A, I or L, X2 is D, G. Ε or P, X, is For L and X4 is I or L
Four additional mixtures. each contaming 1280 peptides
also had all 20 natural amino acids on X()
2.4 51Cr-release assay
s lCr-labeled EBV-transformed Β lymphocytes (2 5 x HP)
were preincubated in 50 μΐ with either naturally eluted or
synthetic peptides for 30 min at 37 °C. HPLC-purtficd
synthetic peptides were tested in final concentrations
between 0 16-5 0 nM. Dned HPLC fractions of the HLA-
A2.1-eluted peptides were resuspended in PBS + 50 mM
Ht pes (usually 250 μΐ) of which 25 μΐ (or serial dilutions)
were added to the wells. Subsequently 100 μΙ 15% human
serum in RPMI with or without (spontaneous release
values) 105 effector cells was added to each well and
mcubated for 4 h at 37 °C. Radioactivity released into the
supernatant was determined in a Packard γ-counter. Spon-
taneous release values for EBV-BLCL were 19-32%
3 Results
HLA-A2.1 was punfied by affinity chromatography [9]
from an HLA-A2.1 + EBV-BLCL expressing both H-Yand
HA-2 minor Η antigens. In total 3.3 mg protein was eluted
from the anti-HLA-A2.1 mAb-coated columns. SDS-
PAGE and reverse-ohase HPLC revealed that this matenal
mainly represented ß2-microglobulin (ß2m) and Η chain
(Fig la, b). Quantification of the HPLC ß2m peak, by
companson with peak sizes of known amounts punfied
ß2m, indicated that 127 μg or 2.35 nmol HLA-A2.1 was
recovered alter HPLC. Naturally bound peptides co-
punfied with HLA-A2.1 were separated from ß2m and
Η chain by acid treatment followed by ultrafiltration (cutoff
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Figure 2. HLA-A2.1 peptide fraction 18 contains minor HA-2.
The peptide content from 2.35 nmol HLA-A2.1 affinity-punfied
from EBV-BLCL of a male. HLA-A2. minor HA-2-expressing
individual was separated by reverse-phase HPLC (A). Individual
l-ml fractions were tested for containing minor peptides H-Y and
HA-2 by incubating 1/60 of each fraction with HLA-A2.1 + ,
HA-2", Η Ύ " BLCL in the absence (open symboJs) or presence
(closed symbols) of the HLA-A2-restncted anti-HY CTL clone
1R35 (B) or anti-HA-2 CTL clone. 5H17 (C) at E/T=40. Positive
fraction 18 was retested in titrated amounts (1/60-1/1920 of
fraction 18; total peptide pool content: 2.35 nmol) for recognition
by HLA-A2-restricted anti-HA-2 CTL (D) and was compared to
the original HLA-A2+. HA-2+ donor BLCL without added
peptide (D, • ) .
10 kDa). Low molecular mass molecules (< 10 kDa) were
fractionated by reverse-phase HPLC (Fig. 2A). Individual
fractions were then tested for recognition by HLA-A2.1-
restricted CTL specific for H-Y (Fig. 2B) and for HA-2
(Fig. 2C). None of the fractions rendered HLA-A2.1 +
female EBV-BLCL susceptible to lysis by anti-H-Y CTL
(Fig. 2B). In contrast. HLA-A2.1\ HA-2~ BLCL incu-
bated with fraction 18 were effectively lysed by anti-HA-2
CTL (Fig. 2C). whereas none of the other fractions could
sensitize the target cells for HA-2. Fraction 18 could be
diluted more than 2000-fold and still sensitize target cells
for HA-2 recognition (Fig. 2D). Comparable HA-2-sensi-
tizing activity was found in HPLC fraction 18 of unsepa-
rated HLA-A2.1. but not in the high molecular mass
(> 10 kDA) material of filtered HLA-A2.1 (not shown).
HA-2 reproducibly eluted in one fraction at a constant
position in the HPLC spectrum. Repeated Isolation of the
peptide content of HLA-A2.1 molecules derived from
4 x 1010 EBV-BLCL yielded identical results (data not
shown).
The HA-2-containing fraction 18 was sequenced by Edman
degradation and found to contain more than one peptide
(Table 1). None of the peptides was more than nine amino
acids in length. Α dominant Leu was found at positions 2
and 9. Tb obtain a purer fraction. containing only the HA-2
peptide, a second HLA-A2.1 peptide pool was separated
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Table 1. Detected ammo acids in minor HA-."1 coinaimns; Iraition
18 at positions 1-9"
1
-W
2
L
3
P»
Α
I
Ε
4
D
G
Ε
Ρ
5
F
L
6
I
L
7
Ε
L
Α
I
8
Τ
9
L
a) HPLC peptide fraction 18 obtained from 1.77 nmol punlied
HLA-A2 was sequenced by Edmun degradation. N-termm.il
peptide yield was 107 pmol decrcasing to 20 pmol ai ι he
C-termnal position 9. Deteclion limil was 5 pmol Nu sjgnili-
cant levels were detected beyond position 9.
b) Significant amounts of all 20 ammo acids were found a( posi-
tion 1.
c) Significant amounts of the ammo acids indicated were
found.
by HPLC using a shallower gradient (20-50% in 45 min
with 0.5 ml fractions instead of 5-75% in 30 min with 1 ml
fractions). Subsequent cell-mediated lysis analysis indi-
cated two fractions with HA-2 activity. However, sequenee
analysis of the pooled fractions revealed again a nonapep-
tide mixture with virtually identical amino acids as found in
fraction 18 (see Table 1).
To identify which of the eluted nonapeptides represented
the naturally processed HA-2 minor peptide, eight mix-
tures of nonapeptides covering all peptides possibly present
in fraction 18 (see Sect. 2.3) were synthesized, fractionated
by HPLC and tested for their ability to induce lysis by
anti-HA-2 CTL. However, none of the peptide mixtures
could sensitize HA-2" BLCL for recognition by anti-HA-2
CTL at concentrations as high as 500 pM (data not
shown).
4 Discussion
Minor Η antigen HA-2 was initially defined by HLA-
A2.1-restricted CTL isolated from PBL after MHC-identi-
cal, HA-2-mismatched BMT [2]. The HA-2+ phenotype
has a frequency of 95% in the HLA-A2.1+ population [3].
In contrast to the previously isolated murine minor Η
peptides H-Y and H-4b which are ubiquitously expressed,
HA-2 is expressed only by cells of hematopoietic origin
[13]. In the Situation of MHC-matched, HA-2-mismatched
BMT, therefore, these anti HA-2 CTL are not likely to
inflict graft-versus-host (GVH) reactions (GVH-target
tissues, e.g. the skin, does not express HA-2), but might be
involved in the so-called graft-versus-leukemia effect [15].
Here, the natural HA-2 peptide presented by HLA-A2.1 to
CTL is shown to be present within an HLA-A2.1 peptide
fraction containing predominantly nonapeptides with Leu
as dominant amino acid at positions 2 and 9. Thus, this
finding is compatible with two previous reports indicating
that naturally processed HLA-A2.1-bound seif peptides
are mainly nonapeptides and carry Leu at position 2 and
either Leu or Val at the carboxy-terminal position 9 [9, 10].
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Unexpectedly, however, none of the synthetic peptide
mixtures, covenng all nonamenc sequences indicated by
the observed HLA-A2 1 binding motif (Table 1), cou!d
sensitize HA-2~ BLCL for recognition by anti-HA-2 CTL
The failure to detect the HA-2 peptide in the peptide
mixtures based on the observed A2 1 motif might be due to
(1) competition for binding to HLA-A2 1 between the
peptides present in each tested mixture, or (2) absence of
the HA-2 amino acid sequence among the senes of
synthetic peptides tested At this stage we cannot rule out
the first possibihty Additional separate testing will be
required to exclude the possibihty of competition The
second explanation would indicate that the amount of
HA-2 peptide present in fraction 18 was insufficient to be
detected Should fraction 18 (100 pmol total peptide
content based on Edman degradation) contain 20 or more
different peptides in equimolar amounts, 1 of which being
HA-2, then HA-2 would already be below the detection
hmit of the PTH amino acid analyzer used (5 pmol) Given
the recent estimate that the HLA-A2 1 molecules of a
given cell might contain 200 to 1000 distinct nonapeptides
[10], this explanation IS not unhkely These results stress the
enormous sensitivity of a CTL in detecting peptide in the
context of an MHC class I molecule Anti-HA-2 CTL could
detect as little as 1 in 1920 of the matenal of fraction 18
which apparently contamed insufficient of the HA-2 pep-
tide to be measured by Edman degradation Our observa-
tions are in hne with previous reports on the Isolation of
minor Η peptides from lysates of whole cells The munne
H-2b-restncted minor Η antigens H-Y, H-4b and Mapki and
an HLA-B35-restncted antigen were detectable by the
appropnate CTL, but could not be identified as Single
peptides [5-7] Recent sequence analysis of the self-peptide
pool present in HLA-A2 1 and HLA-B27 revealed the
presence of a hmited number of "dominant" peptides which
were present in sufficient amounts to allow sequence
analysis [10, 11] Our mabihty to elucidate the amino acid
sequence within the peptide pool denved from 2 35 nmol
HLA-A2 1 may indicate that this minor Η peptide is not
present in comparable amounts to those "dominant" seif
peptides of which sufficient copies are available to allow
Identification as Single peptides and which determine the
peptide-binding profile In fact, lt can not be excluded at
this point that seif peptides, present in quantities undetect-
able with the current biochemical methods, may not follow
the MHC class I allele-specific binding rules based on the
composition of the abundant peptides The fact that
HLA-A2 1-restncted CTL epitopes exist, defined by syn-
thetic peptides which do not fit the HLA-A2 1 binding
protile determined thus far, would be compatible with this
hypothesis [16, 17] Starting with larger amounts of pun-
fied MHC class I (here 6 x 1010 cells were used, yielding
2 35 nmol pure HLA-A2 1 after HPLC) may allow detec-
tion of these minor peptides and determination of MHC
class I binding profiles in more detail
Our inabihty to detect the H-Y, in contrast to the HA-2,
peptide thus tar could be due to (a) a lower number of ΗΎ
peptides per HLA-A2 1 molecule. (b) mabihty of H-Y to
rcplace endogenously bound seif peptides in vitro due to a
lower aitinit> or (c) selective loss of H-Ydunng punfica-
tion At this point we cannot exclude any of these
possihilmes Future punfication ot H-Y peptides from
icii^er amounts of HLA-A2 1 as suggested earher may
lead to its detection
Although the first human minor Η protein still awaits
Identification, in the mouse polymorphic seif proteins
located in the cytosol [18] and in mitochondria [19], as well
as proteins encoded by retroviral genes [20], can represent
minor Η proteins. ι e induce MHC class I-restncted CTL
and skin-graft rejection From this, it may be concluded
that within any given cell a large source of potential minor
Η proteins might be present Fortunately, based on the
recent understanding of the MHC class I-processing path-
way, it may be expected that only a small and selected
fraction of the total pool of peptides denved from these
proteins will make it to the cell surface, and that again onl>
a selected fraction of these cell surface peptides will
manifest itself as minor Η peptide Cntena resulting in this
peptide selection will include (1) a sufficiently high affinity
for binding to one of the available MHC class I molecules,
(2) presence ofa sufficient number of copies resulting in the
minimal number of MHC-peptide complexes at the cell
surface required forTcell activation [21], and (3) polymor-
phism of the peptide and immunogenicity of the MHC-
peptide complex formed Should, in contrast to the total
number of distinct class I-bound cell surface peptides
(estimated 200-1000 for HLA-A2 1), the number of Τ cell-
activating minor Η peptides per MHC class I allele be
hmited to a few or even one, then clmical apphcations in
minor H-mismatched BMT would beiong to the future
possibihties
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